Welcome to our dedicated page for Cytomx Therapeutics SEC filings (Ticker: CTMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CTMX SEC filings page on Stock Titan provides access to CytomX Therapeutics, Inc. regulatory documents as filed with the U.S. Securities and Exchange Commission. CytomX is a clinical-stage, oncology-focused biopharmaceutical company whose common stock trades on the Nasdaq Global Select Market under the symbol CTMX. Its filings offer detailed information on financial performance, risk factors, and the status of its development programs based on its PROBODY® therapeutic platform.
Investors can use this page to locate periodic reports and current reports on Form 8-K. For example, the company has filed 8-K reports to furnish quarterly financial results and to describe material events, such as updates on the CX-2051 Phase 1 study in colorectal cancer. These filings may discuss revenue from collaborations, research and development expenses, cash and investments, and other financial metrics, as well as narrative business updates.
The filings also provide context on clinical and safety disclosures. In one 8-K, CytomX reported an update on the CTMX-2051-101 Phase 1 study, including enrollment across multiple dose levels of CX-2051 and a treatment-related adverse event, along with the Safety Review Committee’s support for continued study execution. Such documents help readers understand how the company reports clinical progress and safety oversight in an official regulatory format.
Through Stock Titan, these SEC filings are complemented by AI-powered summaries that can help explain complex sections, highlight key points from lengthy reports, and surface items related to topics such as clinical trial status, collaboration revenues, or liquidity. Users interested in CytomX’s oncology pipeline, including varsetatug masetecan/CX-2051 and CX-801, can review the underlying filings alongside these AI-generated insights to form their own view of the company’s disclosures.
CytomX Therapeutics reports 2025 collaboration revenue of $76.2 million, down from $138.1 million as several partnered programs advanced or were paused, while expenses fell after a 40% workforce reduction. The company shifted from $31.9 million net income in 2024 to a $17.4 million net loss in 2025.
R&D spending declined to $68.7 million, with investment concentrated in lead programs Varseta-M and CX‑801. Positive Phase 1 data for Varseta-M in late-line metastatic colorectal cancer showed up to 32% confirmed response rate and median progression-free survival of 7.1 months at the 10 mg/kg dose, with largely manageable side effects and an optimized diarrhea prophylaxis regimen.
As of December 31, 2025, CytomX held $137.1 million in cash, cash equivalents and short-term investments, boosted by a May 2025 equity offering and ATM sales. Management expects this to fund operations into the second quarter of 2027 while advancing Varseta-M toward a potential registrational study and progressing CX‑801 and partnered masked-biologic programs.
CytomX Therapeutics: Kynam Capital Management, LP, Kynam Capital Management GP, LLC and Yue Tang report beneficial ownership of 8,966,077 shares of common stock, equal to 5.29% as of 12/31/2025.
The filing states the holders have shared voting and shared dispositive power over those 8,966,077 shares and lists Delaware and United States citizenships for the reporting entities and person.
OrbiMed Advisors LLC reports beneficial ownership of 3,525,650 shares of CytomX Therapeutics, Inc. common stock, representing 2.1% of the class as of 12/31/2025. OrbiMed has shared voting and dispositive power over these shares, which it holds on behalf of other persons entitled to dividends and sale proceeds.
The filing notes this is ownership of 5 percent or less of CytomX’s common stock. OrbiMed states the securities are not held for the purpose of changing or influencing control of CytomX, and its management committee members each disclaim beneficial ownership of the reported shares.
CytomX Therapeutics, Inc. received an amended Schedule 13G filing showing that Tang Capital Management, Kevin Tang, and related Tang Capital entities now report 0 shares of CytomX common stock beneficially owned, representing 0% of the class as of 12/31/2025.
The amendment, identified as Amendment No. 6, confirms that these reporting persons no longer hold voting or dispositive power over any CytomX shares and state that their holdings are 5 percent or less of the outstanding common stock. The filing also certifies that the securities were not acquired or held for the purpose of changing or influencing control of CytomX.
FMR LLC and Abigail P. Johnson report beneficial ownership of 24,688,109 shares of CytomX Therapeutics, Inc. common stock, representing 14.6% of the class as of 12/31/2025, in this Amendment No. 3 to their Schedule 13G.
The shares are reported as held in the ordinary course of business and not for the purpose of changing or influencing control of CytomX. One or more other persons may receive dividends or sale proceeds from these shares, but no such person holds more than five percent of the outstanding common stock.
CytomX Therapeutics granted equity awards to its Chief Business Officer, Rachael Lester, effective February 2, 2026. The filing shows an award of 20,000 shares of common stock, which the footnotes explain are restricted stock units (RSUs) that convert into one share each as they vest. One-third of these RSUs vest annually on March 15, starting in 2027, as long as she continues as a service provider.
The company also granted a stock option for 50,000 shares at an exercise price of $6.09 per share. This option vests in equal monthly installments over four years from February 2, 2026, becoming fully vested on the fourth anniversary if her service continues. In addition, she received 50,000 Performance Stock Units (PSUs), each representing a right to one share of common stock. One-third of the PSUs vest upon the achievement of each of three clinical milestones, again conditioned on continued service.
CytomX Therapeutics Chief Medical Officer Yu-Waye Chu reported new equity awards. On February 2, 2026, Chu received 75,000 shares of Common Stock in the form of restricted stock units at a price of $0 per share. These RSUs convert into one share of Common Stock per unit, with one-third vesting each year on March 15, starting on March 15, 2027, subject to continued service.
On the same date, Chu was granted a stock option for 300,000 shares of Common Stock at an exercise price of $6.09 per share. One forty-eighth of the option vests monthly starting from February 2, 2026, becoming fully vested on the fourth anniversary of that date, also subject to continued service. After these transactions, Chu beneficially owns 210,725 shares of Common Stock, including 206,000 RSUs.
CytomX Therapeutics reported new equity awards for SVP and Chief Scientific Officer Marcia Belvin. On February 2, 2026 she received 60,000 restricted stock units of common stock at a price of $0, increasing her directly held common stock to 332,252 shares, including 218,958 RSUs.
She was also granted a stock option for 250,000 shares of common stock with a $6.09 exercise price. The option vests in equal monthly installments over four years starting from February 2, 2026, and the RSUs vest in three equal annual installments beginning March 15, 2027, subject to continued service.
CytomX Therapeutics reported new equity awards for its Chief Financial Officer, Christopher Ogden. On February 2, 2026, he acquired a stock option covering 325,000 shares of common stock at an exercise price of $6.09 per share and a grant of 90,000 restricted stock units (RSUs) at no cost.
The option vests in equal monthly installments over four years starting from February 2, 2026, becoming fully vested on the fourth anniversary, subject to continued service. The RSUs vest in three equal annual installments each March 15, beginning March 15, 2027, also subject to his continued service.
CytomX Therapeutics CEO Sean A. McCarthy reported new equity awards. On February 2, 2026, he was granted stock options for 980,000 shares of Common Stock with a $6.09 exercise price, vesting in equal monthly installments over four years from that date and expiring on February 1, 2036.
He also acquired 210,000 shares of Common Stock at $0 as restricted stock units, which vest in three equal annual installments each March 15, starting March 15, 2027, contingent on continued service. After these grants, he beneficially owns 1,197,891 shares directly, including 698,750 RSUs, plus 93,158 shares held indirectly by the Sean A. McCarthy 2018 Trust, for which he serves as trustee.